PHILADELPHIA, Dec. 27, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) reported today that the National Horizon Scanning Centre of the Department of Public Health and Epidemiology at the University of Birmingham, United Kingdom, has published a comprehensive “Report on CFS” (issued Dec. 15, 2007). The report focuses on the growing problems in the UK associated with Chronic Fatigue Syndrome, with specific attention given to Poly I: Poly C12U (Ampligen(r)), an experimental therapeutic developed by Hemispherx as a potential aid in fighting the disease.
